About ArcScan
ArcScan is a publicly listed company based in Golden (United States) founded in 2007. Ultrasound device for micron-resolution anterior chamber imaging is provided. ArcScan has raised $15.21 million across 4 funding rounds from investors including Shanghai Haohai Biological Technology. The company has 18 employees. Its chief executive, as recorded, is Andrew Levien. ArcScan offers products and services including Insight 100 and EyeSeal. Its focus areas include Life Sciences, Ophthalmology, Medical Devices and Imaging. Its competitors include EyeNetra, Smart Vision Labs and PlenOptika; 3 of its 3 listed competitors have raised funding.
Company details
ArcScan has developed an ultrasound-based imaging device for ophthalmologists. The device developed is called Insight 100 that incorporates a transducer to scan the eye in arc-shaped motion. Its curvature approximates the anterior ocular surface to visualize and measure the anterior chamber depth, angle-to-angle width, individual corneal layers, sulcus-to-sulcus width with micron-level precision and repeatability. The device is used for sulcus-to-sulcus width sizing for implantable contact lenses (ICLs), corneal epithelial mapping, aid in the diagnosis of glaucoma and surgical planning. They have received FDA 510(k) clearance and CE Mark for their ArcScan Insight 100 precision ultrasound device.
- Headquarters Golden, United States
- Employees 18
- Stage Public
- SectorsHealthcare
- Website arcscan.com
- Social LinkedIn
- Total Equity Funding$15.21M (USD)
in 4 rounds
- Latest Funding Round$11.5M (USD), Series B
Jul 2021
- Investors
- Employee Count18
Products & Services of ArcScan
ArcScan offers a comprehensive portfolio of products and services, including Insight 100 and EyeSeal.
Robotic ultrasound for precise eye structure scanning and surgical planning.
Device for applications in pIOL sizing and glaucoma management.
Funding Insights of ArcScan
ArcScan has successfully raised a total of $15.21M across 4 strategic funding rounds. The most recent funding activity was a Series B round of $11.5 million completed in July 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $15.21M
- Total Rounds 4
- Last Round Series B — $11.5M
- First Round $250,000
(Jun 2008)
- Investors Count 1
All 4 funding rounds of ArcScan with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2021 | $11.5M | Series B | – | – | |
| Feb 2015 | $3.67M | Series A | – | – | – |
| Nov 2009 | $35,000 | Seed | – | – | – |
| Jun 2008 | $250,000 | Debt – Convertible | – | – | – |
1 investors in total: 1 institutional.
Investors in ArcScan
ArcScan has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Shanghai Haohai Biological Technology.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Absorbable biomedical materials for surgeries are researched, manufactured, and sold. | 2007 | 3healthcare.com | Jinzhong, China |
Investor details for ArcScan
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of ArcScan
22 people are tracked at ArcScan (6 in leadership, 6 in board & advisors, 10 in team); the tracked headcount is 18.
| Name | Role | Group |
|---|---|---|
Andrew Levien | CEO & President | Leadership |
Morris Bellows | Director of RAQA, Quality | Leadership |
Karen Lundquist | Director Of Marketing And Clinical Affairs | Leadership |
J. Erik Giphart | Vice President Of Engineering | Leadership |
Dan Reinstein | Chief Medical Officer | Leadership |
Peter M. Ballachey | Chief Financial Officer | Leadership |
Robert Lin | Director | Board & advisors |
Loren Brown | Director | Board & advisors |
Roger Sun | Director | Board & advisors |
Ramgopal P. Rao | Director | Board & advisors |
Luca M. Sergio | Director | Board & advisors |
John Watson | Co-founder and Chairman | Board & advisors |
Clayton Braden | Manager of Field Service Engineering | Team |
Alondra Bahena-Reza | Mechanical Design Engineer | Team |
Sam Keo | Field Service Engineer | Team |
Naya Ziegler | Quality Engineer | Team |
Heather Duffy | Controller | Team |
Sam Brown | Mechanical Design Engineer | Team |
Sandesh Kulkarni | Intern | Team |
Sam Boytor | Senior Manufacturing Engineer | Team |
2 more people are available in the full profile.
Complete people profiles for ArcScan
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of ArcScan
3 dated milestones of ArcScan across 14 years, from founding to its latest funding, stage changes and deals.
- Founded ArcScan is founded.
- Funding First funding round of $250K.
- Funding Latest funding round, Series B, of $11.5M.
Competitors of ArcScan
ArcScan has 3 listed competitors in our database, 3 of them funded. They include EyeNetra, Smart Vision Labs and PlenOptika.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| eyenetra.com | 2011 | Somerville, United States | $7M | 3 | Refractive errors are measured using smartphone camera attachments. | |
| smartvisionlabs.com | 2013 | New York, United States | $6.1M | Refractive errors are tested via smartphone attachment by healthcare professionals. | ||
| plenoptika.com | 2014 | Cambridge, United States | $50,383 | Developer of a medical devices for measuring refractive errors |
Detailed competitors of ArcScan
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of ArcScan
The website of ArcScan (arcscan.com) receives about 1.2K visits a month.
- Monthly visits1.2K
▲ 643.2% vs previous month
Top companies in Ophthalmology
3 companies that operate in the same segment as ArcScan (Ophthalmology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of a wide range of eye care products | 1945 | Fort Worth, Texas, United States | USD 171.61 M | USD 9.64 B | 25,600 | |
Genetic medicines are developed by 4DMT for transformative therapies. | 2013 | Emeryville, California, United States | USD 186.59 M | USD 85.21 M | 227 | |
Developer of antibodies to treat complement-mediated neurodegenerative diseases | 2011 | San Francisco, California, United States | USD 256 M | 100 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Arcscan
Complete news archive for ArcScan
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about ArcScan
ArcScan was founded in 2007 and raised its 1st funding round 1 year after it was founded.
ArcScan is headquartered in Golden, United States. It is registered at Golden, Colorado, United States.
Andrew Levien is the CEO of ArcScan, as recorded in our data.
ArcScan is a funded company, having raised a total of $15.21M across 4 funding rounds to date. The company's 1st funding round was a Debt – Convertible of $250K, raised on Jun 2008.
ArcScan has 18 employees.
ArcScan has developed an ultrasound-based imaging device for ophthalmologists. The device developed is called Insight 100 that incorporates a transducer to scan the eye in arc-shaped motion. Its curvature approximates the anterior ocular surface to visualize and measure the anterior chamber depth, angle-to-angle width, individual corneal layers, sulcus-to-sulcus width with micron-level precision and repeatability. The device is used for sulcus-to-sulcus width sizing for implantable contact lenses (ICLs), corneal epithelial mapping, aid in the diagnosis of glaucoma and surgical planning. They have received FDA 510(k) clearance and CE Mark for their ArcScan Insight 100 precision ultrasound device.
ArcScan's top competitors include EyeNetra, Smart Vision Labs and PlenOptika.
ArcScan offers Insight 100 and EyeSeal.
ArcScan has 1 investor. Key investors include Shanghai Haohai Biological Technology.